Pont A, Williams P L, Loose D S, Feldman D, Reitz R E, Bochra C, Stevens D A
Ann Intern Med. 1982 Sep;97(3):370-2. doi: 10.7326/0003-4819-97-3-370.
Ketoconazole, a broad-spectrum, antifungal drug that is administered orally, has been shown to inhibit sterol synthesis in fungi. When gynecomastia developed in some patients taking this drug, we investigated the effects of ketoconazole on steroid synthesis in humans and in isolated adrenal cells from rats. In healthy humans, the cortisol response to adrenocorticotropic hormone was significantly blunted 4 hours after a 400-mg or 600-mg dose. The inhibition persisted for up to 8 hours and was absent by 16 hours. This finding indicated that adrenal androgen response was reduced. Easily achieved therapeutic concentrations of ketoconazole virtually eliminated corticosterone production by isolated adrenal cells from rats. Although ketoconazole at currently used doses has never been documented to cause clinical hypoadrenalism, caution is urged in high- or multiple-dose trials. The drug may prove useful as an agent to block steroid synthesis.
酮康唑是一种口服的广谱抗真菌药物,已被证明可抑制真菌中的固醇合成。当一些服用该药物的患者出现乳腺增生时,我们研究了酮康唑对人体及大鼠分离肾上腺细胞中类固醇合成的影响。在健康人体中,服用400毫克或600毫克剂量的酮康唑4小时后,促肾上腺皮质激素引起的皮质醇反应明显减弱。这种抑制作用持续长达8小时,16小时后消失。这一发现表明肾上腺雄激素反应降低。酮康唑易于达到的治疗浓度实际上消除了大鼠分离肾上腺细胞中皮质酮的产生。虽然目前使用剂量的酮康唑从未被记录会导致临床肾上腺功能减退,但在高剂量或多剂量试验中仍需谨慎。该药物可能被证明是一种阻断类固醇合成的有用药物。